Friday, November 22, 2024
Facebook Linkedin Twitter
HomeTagsTARRYTOWN

TARRYTOWN

Healthcare

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

PR Newswire -
Regeneron Pharmaceuticals, Inc and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us